Lanreotide LAR (Somatuline Depot)

General information

Class/mechanism: Long-acting dosage form of Lanreotide (Somatuline).

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.

Diseases for which it is used

• Neuroendocrine tumor

History of changes in FDA indication

• 2007-08-30: Initial FDA approval

History of changes in Health Canada indication

• 2006-07-17: Initial notice of compliance for long-term treatment of patients with acromegaly due to pituitary tumours who have had inadequate response to or cannot be treated with surgery and/or radiotherapy.
• 2006-07-17: Initial notice of compliance for relief of symptoms associated with acromegaly.
• 2015-09-28: New indication for the treatment of enteropancreatic neuroendocrine tumors in patients with unsectable, locally advanced or metastatic disease.
• 2018-02-02: New indication for the treatment of adult patients with carcinoid syndrome.

Also known as

• Generic names: lanreotide long-acting release
• Brand names: Somatuline Depot